{"product_id":"rmd-bcg-matrix","title":"ResMed Inc. (RMD): BCG Matrix [June-2026 Updated]","description":"\u003cp\u003eThis ready-made analysis gives you a practical, research-based view of Company Name's portfolio, showing where growth is strongest, where cash is being generated, and which bets still need proof. You'll see why devices, masks, and software matter at \u003cstrong\u003e51%\u003c\/strong\u003e, \u003cstrong\u003e37%\u003c\/strong\u003e, and \u003cstrong\u003e12%\u003c\/strong\u003e of revenue, how Q2 and Q3 2026 revenue both grew \u003cstrong\u003e11%\u003c\/strong\u003e year over year to about \u003cstrong\u003e$1.42B\u003c\/strong\u003e to \u003cstrong\u003e$1.43B\u003c\/strong\u003e, and how new moves such as Noctrix, Smart Comfort, and the ŌURA partnership fit into the capital-allocation picture. It also helps you connect margin strength above \u003cstrong\u003e62%\u003c\/strong\u003e, operating cash flow of \u003cstrong\u003e$554M\u003c\/strong\u003e in Q3 2026, and the \u003cstrong\u003e$0.60\u003c\/strong\u003e quarterly dividend to a clear view of portfolio balance, relative share, and which areas look ready for investment, harvesting, or further testing.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - BCG Matrix Analysis: Stars\u003c\/h2\u003e\n\n\u003cp\u003eResMed Inc.'s \u003cstrong\u003eStars\u003c\/strong\u003e are the businesses with high market growth and high relative share that deserve the most investment. In this case, the device platform, AI therapy layer, mask innovation, and connected care stack all fit that profile because they combine strong demand, scale, and recurring usage.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eStar Area\u003c\/td\u003e\n\u003ctd\u003eWhy It Fits the BCG Star Category\u003c\/td\u003e\n\u003ctd\u003eKey Data Point\u003c\/td\u003e\n\u003ctd\u003eWhy It Matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice platform\u003c\/td\u003e\n\u003ctd\u003eHigh growth, high share in core respiratory care\u003c\/td\u003e\n \u003ctd\u003eDevices were 51% of revenue as of March 31, 2026; Q3 2026 revenue was $1.43B\u003c\/td\u003e\n \u003ctd\u003eThis shows scale and ongoing demand in the core franchise\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI therapy acceleration\u003c\/td\u003e\n\u003ctd\u003eNew product category with clear adoption potential\u003c\/td\u003e\n \u003ctd\u003eSmart Comfort received FDA clearance on December 8, 2025\u003c\/td\u003e\n \u003ctd\u003eRegulatory approval creates a path to commercial expansion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMask innovation momentum\u003c\/td\u003e\n\u003ctd\u003eLarge installed base and repeated replacement demand\u003c\/td\u003e\n \u003ctd\u003eMasks and other products were 37% of revenue as of March 31, 2026\u003c\/td\u003e\n \u003ctd\u003eStrong mix supports margins and keeps the product line strategically important\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected care scale\u003c\/td\u003e\n\u003ctd\u003eNetwork effects and sticky software usage\u003c\/td\u003e\n \u003ctd\u003e36M patient enrollments in AirView and 34M cloud-connected devices worldwide\u003c\/td\u003e\n \u003ctd\u003eA larger ecosystem improves retention, monitoring, and cross-selling\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDevice platform leadership\u003c\/strong\u003e is the clearest Star. ResMed's devices business represented \u003cstrong\u003e51%\u003c\/strong\u003e of revenue as of March 31, 2026, and Q3 2026 revenue reached \u003cstrong\u003e$1.43B\u003c\/strong\u003e. Revenue growth stayed at \u003cstrong\u003e11%\u003c\/strong\u003e year over year in both Q2 and Q3 2026, which is strong for a scaled respiratory platform. GAAP gross margin was \u003cstrong\u003e62.2%\u003c\/strong\u003e in Q3 2026, while FY2026 guidance calls for \u003cstrong\u003e62% to 63%\u003c\/strong\u003e, showing pricing power and favorable product mix. The U.S. sleep apnea pool was estimated at \u003cstrong\u003e77M\u003c\/strong\u003e people, and Philips Respironics still could not sell new sleep therapy devices in the U.S. in January 2026. That combination supports both high growth and high relative share.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic point is simple: a Star must keep winning while the market expands. ResMed's device franchise does that because it sits in a large underpenetrated market, it has scale, and it still grows at double digits. For academic analysis, this is a strong example of how a mature company can still have Star assets if the category remains large and the company keeps taking share.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI therapy acceleration\u003c\/strong\u003e is another Star because it adds growth on top of the core device base. Smart Comfort received FDA clearance on December 8, 2025 and entered a limited U.S. beta rollout in early 2026 for new myAir users on AirSense 11 devices. That matters because AI features can improve comfort, adherence, and patient experience, which can raise retention and device utilization.\u003c\/p\u003e\n\n\u003cp\u003eResMed's digital ecosystem already includes \u003cstrong\u003e36M\u003c\/strong\u003e patient enrollments in AirView and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices worldwide as of March 31, 2026. FY2025 R\u0026amp;D spending was \u003cstrong\u003e$400M\u003c\/strong\u003e, or about \u003cstrong\u003e8%\u003c\/strong\u003e of revenue, and FY2026 guidance still calls for R\u0026amp;D at \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e of revenue. That level of spending shows the company can keep funding product innovation. Q3 2026 non-GAAP EPS was \u003cstrong\u003e$2.86\u003c\/strong\u003e and operating cash flow was \u003cstrong\u003e$554M\u003c\/strong\u003e, which means the company can support rollout without putting pressure on the balance sheet.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFDA clearance lowers commercialization risk.\u003c\/li\u003e\n \u003cli\u003eLarge connected-user scale supports faster adoption.\u003c\/li\u003e\n \u003cli\u003eStrong operating cash flow supports ongoing R\u0026amp;D.\u003c\/li\u003e\n \u003cli\u003eAI features can deepen customer stickiness, which is critical in a Star.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMask innovation momentum\u003c\/strong\u003e also belongs in Stars because it combines product refresh with a large market base. AirTouch F30i Comfort launched in the U.S. on February 11, 2026 after earlier releases in Australia and Canada. Masks and other products accounted for \u003cstrong\u003e37%\u003c\/strong\u003e of revenue as of March 31, 2026, making the category a major growth and profit pool. Q2 2026 revenue was \u003cstrong\u003e$1.42B\u003c\/strong\u003e and Q3 2026 revenue was \u003cstrong\u003e$1.43B\u003c\/strong\u003e, both up \u003cstrong\u003e11%\u003c\/strong\u003e year over year.\u003c\/p\u003e\n\n\u003cp\u003eThe margin trend strengthens the case. FY2025 revenue was \u003cstrong\u003e$5.15B\u003c\/strong\u003e with \u003cstrong\u003e10%\u003c\/strong\u003e growth, and gross margin improved from \u003cstrong\u003e59.2%\u003c\/strong\u003e in FY2025 to above \u003cstrong\u003e62%\u003c\/strong\u003e in fiscal 2026 quarters. That means mask innovation is not just adding volume; it is also supporting profit quality. The large U.S. sleep apnea addressable market and Philips' ongoing U.S. device restriction give new mask launches an attractive demand backdrop.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eConnected care scale\u003c\/strong\u003e is a Star because it creates an installed-base advantage. AirView enrollment reached \u003cstrong\u003e36M\u003c\/strong\u003e patients and cloud-connected devices reached \u003cstrong\u003e34M\u003c\/strong\u003e worldwide by March 31, 2026. Residential care software still represented \u003cstrong\u003e12%\u003c\/strong\u003e of revenue, so the software layer is already material rather than experimental. The May 19, 2026 partnership with ŌURA expands sleep data integration and patient education, adding another ecosystem path.\u003c\/p\u003e\n\n\u003cp\u003eThis business matters because connected care increases switching costs. Once patients, providers, and devices are tied into the platform, ResMed can improve adherence tracking, data visibility, and follow-on product use. Q1 2026 operating cash flow was \u003cstrong\u003e$457M\u003c\/strong\u003e and Q3 2026 operating cash flow was \u003cstrong\u003e$554M\u003c\/strong\u003e, showing the network is producing cash while it scales. In BCG terms, this is a high-growth platform with strong installed-base leverage.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2026\u003c\/td\u003e\n\u003ctd\u003eQ3 2026\u003c\/td\u003e\n\u003ctd\u003eInterpretation for Stars\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.42B\u003c\/td\u003e\n\u003ctd\u003e$1.43B\u003c\/td\u003e\n\u003ctd\u003eConsistent double-digit growth supports Star status\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-year growth\u003c\/td\u003e\n\u003ctd\u003e11%\u003c\/td\u003e\n\u003ctd\u003e11%\u003c\/td\u003e\n\u003ctd\u003eShows durable demand rather than a one-time spike\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP gross margin\u003c\/td\u003e\n\u003ctd\u003eAbove 62%\u003c\/td\u003e\n\u003ctd\u003e62.2%\u003c\/td\u003e\n\u003ctd\u003eIndicates pricing power and product mix strength\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating cash flow\u003c\/td\u003e\n\u003ctd\u003eNot stated here\u003c\/td\u003e\n\u003ctd\u003e$554M\u003c\/td\u003e\n\u003ctd\u003eProvides funding for R\u0026amp;D, AI, and connected care investment\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor strategy analysis, these Stars show why ResMed can keep investing in innovation instead of defending a weak portfolio. The device platform builds the base, AI improves the treatment experience, masks capture replacement and upgrade demand, and connected care increases retention. That combination is exactly what you want in a Star: strong market position, scalable economics, and room for reinvestment.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - BCG Matrix Analysis: Cash Cows\u003c\/h2\u003e\n\n\u003cp\u003eResMed Inc.'s cash cows are the recurring mask franchise, the core device base, and the software layer tied to patient monitoring. These businesses combine high market share with steady demand, which produces strong cash flow with limited need for heavy reinvestment.\u003c\/p\u003e\n\n\u003cp\u003eThe cash cow profile is visible in the margin structure, recurring revenue mix, and shareholder returns. Gross margin improved from \u003cstrong\u003e59.2%\u003c\/strong\u003e in FY2025 to \u003cstrong\u003e62.3%\u003c\/strong\u003e in Q2 2026 and \u003cstrong\u003e62.2%\u003c\/strong\u003e in Q3 2026, while operating cash flow stayed strong at \u003cstrong\u003e$457M\u003c\/strong\u003e in Q1 2026 and \u003cstrong\u003e$554M\u003c\/strong\u003e in Q3 2026. That is the pattern you expect from mature businesses that generate cash more reliably than they consume it.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Cow Area\u003c\/td\u003e\n\u003ctd\u003eRevenue Indicator\u003c\/td\u003e\n\u003ctd\u003eWhy It Fits the BCG Cash Cow Profile\u003c\/td\u003e\n\u003ctd\u003eStrategic Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring masks\u003c\/td\u003e\n\u003ctd\u003eMasks and other products contributed \u003cstrong\u003e37%\u003c\/strong\u003e of revenue as of March 31, 2026\u003c\/td\u003e\n \u003ctd\u003eProducts wear out and must be replaced, so demand repeats without major new customer acquisition costs\u003c\/td\u003e\n \u003ctd\u003eProvides steady cash and supports dividend capacity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore devices\u003c\/td\u003e\n\u003ctd\u003eDevices generated \u003cstrong\u003e51%\u003c\/strong\u003e of revenue in March 2026 and anchored Q3 2026 revenue of \u003cstrong\u003e$1.43B\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eLarge installed base keeps monetization stable even when growth slows\u003c\/td\u003e\n \u003ctd\u003eFunds capital returns and ongoing operations\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResidential care software\u003c\/td\u003e\n\u003ctd\u003eSoftware accounted for \u003cstrong\u003e12%\u003c\/strong\u003e of revenue at March 31, 2026\u003c\/td\u003e\n \u003ctd\u003eRecurring, sticky, and built on top of connected devices and patient data\u003c\/td\u003e\n \u003ctd\u003eRaises lifetime value per patient and lowers churn risk\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecurring mask annuities\u003c\/strong\u003e are a classic cash cow. Masks and related products made up \u003cstrong\u003e37%\u003c\/strong\u003e of revenue as of March 31, 2026, and the business is naturally recurring because masks wear out and need replacement. FY2025 revenue reached \u003cstrong\u003e$5.15B\u003c\/strong\u003e, up \u003cstrong\u003e10%\u003c\/strong\u003e year over year, which shows the installed base is still monetizing at scale. The installed base matters because ResMed had \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices and \u003cstrong\u003e36M\u003c\/strong\u003e AirView patients supporting repeat usage. The company also continued returning cash, including a \u003cstrong\u003e$0.60\u003c\/strong\u003e quarterly dividend declared on April 30, 2026 after paying the prior \u003cstrong\u003e$0.60\u003c\/strong\u003e dividend on March 19, 2026. This is the kind of stable, replenishing revenue stream that BCG labels a cash cow.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCore device harvest\u003c\/strong\u003e is the other major cash engine. Devices still generated \u003cstrong\u003e51%\u003c\/strong\u003e of revenue in March 2026, and Q3 2026 revenue reached \u003cstrong\u003e$1.43B\u003c\/strong\u003e. Operating cash flow was \u003cstrong\u003e$554M\u003c\/strong\u003e in Q3 2026 and \u003cstrong\u003e$457M\u003c\/strong\u003e in Q1 2026, which shows strong conversion from sales into cash. ResMed repurchased \u003cstrong\u003e523K\u003c\/strong\u003e shares for \u003cstrong\u003e$150M\u003c\/strong\u003e in Q1 2026, which signals that management sees excess cash beyond what the business needs for day-to-day operations. FY2026 guidance keeps SG\u0026amp;A at \u003cstrong\u003e19%\u003c\/strong\u003e to \u003cstrong\u003e20%\u003c\/strong\u003e of revenue and R\u0026amp;D at \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e of revenue, which limits reinvestment drag and leaves more cash available for shareholders.\u003c\/p\u003e\n\n\u003cp\u003eThe market context also supports this cash cow classification. Philips' U.S. sales restriction reduced pressure in a key competitive area, while ResMed's operations across \u003cstrong\u003e140\u003c\/strong\u003e countries support broad monetization without relying on one market. In BCG terms, that means the business can harvest cash from a large installed base instead of spending aggressively to defend share at all costs. That matters because cash cows are supposed to fund the rest of the portfolio, not absorb it.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSoftware install base\u003c\/strong\u003e is the sticky cash-generating layer. Residential Care Software accounted for \u003cstrong\u003e12%\u003c\/strong\u003e of revenue at March 31, 2026, and it sits on top of a \u003cstrong\u003e36M\u003c\/strong\u003e-patient AirView base and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices. That makes the software business recurring and relatively capital light, because the company is monetizing an existing network rather than building new physical capacity. Q2 2026 revenue was \u003cstrong\u003e$1.42B\u003c\/strong\u003e and Q3 2026 revenue was \u003cstrong\u003e$1.43B\u003c\/strong\u003e, both up \u003cstrong\u003e11%\u003c\/strong\u003e year over year, while gross margin stayed above \u003cstrong\u003e62%\u003c\/strong\u003e. FY2025 R\u0026amp;D spend was \u003cstrong\u003e$400M\u003c\/strong\u003e, about \u003cstrong\u003e8%\u003c\/strong\u003e of revenue, but FY2026 guidance lowered R\u0026amp;D to \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e, showing tighter spending discipline and stronger monetization from the software layer.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThe software base increases switching costs because patients, providers, and connected devices are already linked into the system.\u003c\/li\u003e\n \u003cli\u003eRecurring subscriptions and service revenue improve predictability compared with one-time product sales.\u003c\/li\u003e\n \u003cli\u003eThe software layer supports lower incremental cost per added user, which helps margin expansion.\u003c\/li\u003e\n \u003cli\u003eCash from software can fund product upgrades and newer growth bets without pressuring the balance sheet.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCapital return engine\u003c\/strong\u003e is the financial result of these cash cows. ResMed had \u003cstrong\u003e145.06M\u003c\/strong\u003e common shares outstanding and \u003cstrong\u003e45.83M\u003c\/strong\u003e treasury shares as of March 31, 2026. It continued returning capital through a \u003cstrong\u003e$0.60\u003c\/strong\u003e quarterly dividend and a \u003cstrong\u003e$150M\u003c\/strong\u003e share repurchase in Q1 2026. Q2 2026 net income was \u003cstrong\u003e$392.6M\u003c\/strong\u003e, and Q3 2026 operating cash flow was \u003cstrong\u003e$554M\u003c\/strong\u003e, so the cash engine remained strong enough to support payouts while still funding operations. FY2026 gross margin guidance of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e and tax guidance of \u003cstrong\u003e21%\u003c\/strong\u003e to \u003cstrong\u003e23%\u003c\/strong\u003e leave room for distributions, which is exactly what you expect from a cash cow rather than a capital-hungry growth unit.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFY2025 \/ Q1 2026 \/ Q2 2026 \/ Q3 2026\u003c\/td\u003e\n\u003ctd\u003eBCG Cash Cow Signal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.15B\u003c\/strong\u003e FY2025; \u003cstrong\u003e$1.42B\u003c\/strong\u003e Q2 2026; \u003cstrong\u003e$1.43B\u003c\/strong\u003e Q3 2026\u003c\/td\u003e\n \u003ctd\u003eLarge, stable revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e59.2%\u003c\/strong\u003e FY2025; \u003cstrong\u003e62.3%\u003c\/strong\u003e Q2 2026; \u003cstrong\u003e62.2%\u003c\/strong\u003e Q3 2026\u003c\/td\u003e\n \u003ctd\u003eStrong pricing power and efficient delivery\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating cash flow\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$457M\u003c\/strong\u003e Q1 2026; \u003cstrong\u003e$554M\u003c\/strong\u003e Q3 2026\u003c\/td\u003e\n \u003ctd\u003eHigh cash conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder returns\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.60\u003c\/strong\u003e dividend; \u003cstrong\u003e$150M\u003c\/strong\u003e buyback\u003c\/td\u003e\n \u003ctd\u003eExcess cash available after core reinvestment\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong recurring demand from masks creates dependable replacement sales.\u003c\/li\u003e\n \u003cli\u003eDevices anchor the revenue base and support continued monetization of an installed base.\u003c\/li\u003e\n \u003cli\u003eSoftware adds sticky, lower-capital revenue on top of the hardware ecosystem.\u003c\/li\u003e\n \u003cli\u003eHigh gross margins and strong operating cash flow support dividends and buybacks.\u003c\/li\u003e\n \u003cli\u003eModerate R\u0026amp;D and SG\u0026amp;A guidance show disciplined reinvestment rather than aggressive expansion spending.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eResMed Inc. - BCG Matrix Analysis: Question Marks\u003c\/h2\u003e\n\u003cp\u003eThese businesses fit the \u003cstrong\u003equestion marks\u003c\/strong\u003e quadrant because they sit in attractive growth areas, but ResMed Inc. has not yet shown clear market share, revenue contribution, or payback. The strategic issue is not funding; it is whether each initiative can turn distribution, product access, and clinical credibility into durable share.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eInitiative\u003c\/th\u003e\n\u003cth\u003eLaunch \/ Event\u003c\/th\u003e\n\u003cth\u003eWhy It Fits Question Marks\u003c\/th\u003e\n\u003cth\u003eKey Evidence\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNoctrix adjacency bet\u003c\/td\u003e\n\u003ctd\u003eJune 1, 2026 acquisition\u003c\/td\u003e\n\u003ctd\u003eAdjacent market, no disclosed revenue yet\u003c\/td\u003e\n \u003ctd\u003e$340M purchase, no revenue contribution disclosed\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmart Comfort test bed\u003c\/td\u003e\n\u003ctd\u003eDecember 8, 2025 clearance; early 2026 beta\u003c\/td\u003e\n \u003ctd\u003ePromising feature with no standalone economics disclosed\u003c\/td\u003e\n \u003ctd\u003eLimited rollout to new myAir users with AirSense 11\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eŌURA partnership\u003c\/td\u003e\n\u003ctd\u003eMay 19, 2026\u003c\/td\u003e\n\u003ctd\u003eGrowth option without proven share or revenue\u003c\/td\u003e\n \u003ctd\u003eExtends beyond 12% residential care software mix\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAirTouch F30i Comfort\u003c\/td\u003e\n\u003ctd\u003eU.S. launch on February 11, 2026\u003c\/td\u003e\n\u003ctd\u003eNew format with no disclosed unit economics\u003c\/td\u003e\n \u003ctd\u003eMask segment is 37% of revenue, but line-level share is unknown\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eNoctrix adjacency bet\u003c\/strong\u003e is a classic question mark because it enters a related but still unproven category. Noctrix Health focuses on wearable therapeutic devices for neurological disorders, which sits outside ResMed Inc.'s current mix of \u003cstrong\u003e51%\u003c\/strong\u003e devices, \u003cstrong\u003e37%\u003c\/strong\u003e masks, and \u003cstrong\u003e12%\u003c\/strong\u003e software. The \u003cstrong\u003e$340M\u003c\/strong\u003e acquisition on June 1, 2026 gives ResMed Inc. a new platform, but no revenue contribution has been disclosed, so you cannot yet tell whether the deal will become a star or stay a niche asset. The good news is that the company has room to invest: FY2025 R\u0026amp;D was \u003cstrong\u003e$400M\u003c\/strong\u003e, or about \u003cstrong\u003e8%\u003c\/strong\u003e of revenue, and FY2026 guidance still calls for \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e of revenue. With Q3 2026 gross margin at \u003cstrong\u003e62.2%\u003c\/strong\u003e and FY2026 guidance of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e, the main risk is adoption and share capture, not financial stress.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrategic fit: adjacent to core respiratory and sleep health capabilities.\u003c\/li\u003e\n \u003cli\u003eFinancial profile: funded without a near-term margin crisis.\u003c\/li\u003e\n \u003cli\u003eBCG issue: no visible proof of demand, revenue, or market share yet.\u003c\/li\u003e\n \u003cli\u003eAcademic angle: use this case to show how acquisition-led expansion can create a question mark even when the buyer is profitable.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSmart Comfort test bed\u003c\/strong\u003e is another question mark because it has regulatory clearance and distribution access, but no proven economic result. The feature received FDA clearance on December 8, 2025 and entered a limited U.S. beta rollout in early 2026. It is being offered to new myAir users paired with AirSense 11 devices, which matters because ResMed Inc. already has \u003cstrong\u003e36M\u003c\/strong\u003e AirView patient enrollments and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices. That installed base gives the company a low-cost way to test adoption, user engagement, and possible device attachment. Still, no standalone revenue or market share has been disclosed. Q3 2026 non-GAAP EPS was \u003cstrong\u003e$2.86\u003c\/strong\u003e and operating cash flow was \u003cstrong\u003e$554M\u003c\/strong\u003e, so the company has the internal cash generation to keep testing the feature while waiting for evidence.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSmart Comfort Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eWhy It Matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA clearance date\u003c\/td\u003e\n\u003ctd\u003eDecember 8, 2025\u003c\/td\u003e\n\u003ctd\u003eShows regulatory readiness, which is necessary but not enough for success\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRollout timing\u003c\/td\u003e\n\u003ctd\u003eEarly 2026\u003c\/td\u003e\n\u003ctd\u003eIndicates the feature is still in market testing mode\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution base\u003c\/td\u003e\n\u003ctd\u003e36M AirView enrollments and 34M connected devices\u003c\/td\u003e\n \u003ctd\u003eLarge installed base can speed adoption if the feature proves useful\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2026 non-GAAP EPS\u003c\/td\u003e\n\u003ctd\u003e$2.86\u003c\/td\u003e\n\u003ctd\u003eShows earnings power that supports experimentation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2026 operating cash flow\u003c\/td\u003e\n\u003ctd\u003e$554M\u003c\/td\u003e\n\u003ctd\u003eShows liquidity to fund trials and user education\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eŌURA partnership experiment\u003c\/strong\u003e extends ResMed Inc. into sleep data integration and sleep health education, but it still lacks proof of market position. The partnership announced on May 19, 2026 goes beyond the company's current \u003cstrong\u003e12%\u003c\/strong\u003e residential care software mix and uses the \u003cstrong\u003e34M\u003c\/strong\u003e connected-device base as a distribution channel. That makes it strategically relevant, because a software and data layer can increase user engagement and create more reasons to stay inside the ecosystem. Yet the partnership does not disclose revenue or share, so the market still has no way to judge whether this is a small add-on or a scaled growth engine. The core business can support the experiment: FY2025 revenue was \u003cstrong\u003e$5.15B\u003c\/strong\u003e, Q2 and Q3 2026 both grew \u003cstrong\u003e11%\u003c\/strong\u003e year over year, and gross margin stayed at \u003cstrong\u003e62.2%\u003c\/strong\u003e in Q3 2026 with FY2026 guidance of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrategic logic: expands sleep-health reach beyond devices into data and education.\u003c\/li\u003e\n \u003cli\u003eRevenue visibility: none disclosed, which keeps it in question mark territory.\u003c\/li\u003e\n \u003cli\u003eOperating support: strong core growth gives management time to test and refine.\u003c\/li\u003e\n \u003cli\u003eAcademic angle: useful for discussing platform expansion and ecosystem strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAirTouch F30i Comfort\u003c\/strong\u003e is strategically relevant because it targets the mask business, which remains a large part of ResMed Inc.'s mix at \u003cstrong\u003e37%\u003c\/strong\u003e of revenue. The U.S. launch on February 11, 2026 followed earlier releases in Australia and Canada, so the company is using multi-country learnings to test the format. But as of June 2026, there is no disclosed market share, unit volume, or ROI for the F30i line. That missing evidence matters because BCG classification depends on both growth and relative market position. ResMed Inc. has the earnings and expense capacity to test the format during a period of \u003cstrong\u003e10%\u003c\/strong\u003e FY2025 revenue growth and \u003cstrong\u003e11%\u003c\/strong\u003e growth in both Q2 and Q3 2026, while SG\u0026amp;A guidance stayed at \u003cstrong\u003e19%\u003c\/strong\u003e to \u003cstrong\u003e20%\u003c\/strong\u003e of revenue. This means the launch can be evaluated without pressure on the broader business.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eAirTouch F30i Comfort Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eInterpretation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. launch date\u003c\/td\u003e\n\u003ctd\u003eFebruary 11, 2026\u003c\/td\u003e\n\u003ctd\u003eRecent launch means performance is still early and uncertain\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarlier markets\u003c\/td\u003e\n\u003ctd\u003eAustralia and Canada\u003c\/td\u003e\n\u003ctd\u003eShows controlled international testing before U.S. rollout\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMask and other products share\u003c\/td\u003e\n\u003ctd\u003e37% of revenue\u003c\/td\u003e\n\u003ctd\u003eLarge segment gives room to test new formats\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A guidance\u003c\/td\u003e\n\u003ctd\u003e19% to 20% of revenue\u003c\/td\u003e\n\u003ctd\u003eMarketing and selling costs are contained, leaving room for experimentation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 revenue growth\u003c\/td\u003e\n\u003ctd\u003e10%\u003c\/td\u003e\n\u003ctd\u003eStrong base growth supports new product testing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 and Q3 2026 growth\u003c\/td\u003e\n\u003ctd\u003e11% year over year\u003c\/td\u003e\n\u003ctd\u003eSignals that the core business can absorb launch risk\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor BCG analysis, these four initiatives should stay in the question marks bucket until you can observe three things: revenue contribution, share capture, and repeat usage. Without those signals, you cannot move them into stars. The practical implication is that ResMed Inc. is using its cash flow, margin, and installed base to buy time while the market decides whether these ideas deserve bigger investment.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - BCG Matrix Analysis: Dogs\u003c\/h2\u003e\n\n\u003cp\u003eResMed Inc. does not show a clear, disclosed business segment that fits the classic BCG \u003cstrong\u003edog\u003c\/strong\u003e profile of low market share and low growth. The company's operating mix is still led by devices at \u003cstrong\u003e51%\u003c\/strong\u003e of revenue, masks at \u003cstrong\u003e37%\u003c\/strong\u003e, and software at \u003cstrong\u003e12%\u003c\/strong\u003e, and all three sit inside a business that grew \u003cstrong\u003e11%\u003c\/strong\u003e year over year to \u003cstrong\u003e$1.43B\u003c\/strong\u003e in Q3 2026.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eBCG Matrix Reading\u003c\/th\u003e\n\u003cth\u003eWhy It Matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e51%\u003c\/strong\u003e of revenue; Q3 2026 company revenue up \u003cstrong\u003e11%\u003c\/strong\u003e to \u003cstrong\u003e$1.43B\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eNot a dog\u003c\/td\u003e\n\u003ctd\u003eLarge revenue base and continued growth argue against low-share, low-growth status\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMasks\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e37%\u003c\/strong\u003e of revenue\u003c\/td\u003e\n\u003ctd\u003eNot a dog\u003c\/td\u003e\n\u003ctd\u003eStill a major revenue contributor inside a growing core business\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12%\u003c\/strong\u003e of revenue\u003c\/td\u003e\n\u003ctd\u003eNot enough evidence for dog classification\u003c\/td\u003e\n \u003ctd\u003eSmaller mix, but still part of an expanding platform business\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-core overhead\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6M\u003c\/strong\u003e restructuring charge on April 30, 2026\u003c\/td\u003e\n \u003ctd\u003eClosest dog-like item\u003c\/td\u003e\n\u003ctd\u003eRepresents transition cost, not a market-facing business unit\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe strongest case for a dog-like reading sits outside revenue-generating operations. ResMed recorded \u003cstrong\u003e$6M\u003c\/strong\u003e of restructuring charges on April 30, 2026 tied to workforce planning and severance benefits. Those costs reflect change management, not a business line that sells into the market. The company also completed a CFO transition, with Brett Sandercock retiring and Aaron Bloomer taking the role effective May 4, 2026. These are organizational costs, so they can be treated as dog-like tail items in a portfolio lens, but not as a true operating segment.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRestructuring charges are cost items, not revenue engines.\u003c\/li\u003e\n \u003cli\u003eLeadership transition costs affect execution, not market share.\u003c\/li\u003e\n \u003cli\u003eProduct-led 2030 operating model changes support efficiency, but they do not create a separate business unit.\u003c\/li\u003e\n \u003cli\u003eThat makes them closer to BCG dog quadrant noise than to a strategic asset.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHedging and treasury activity also do not qualify as a dog business. As of March 31, 2026, ResMed reported \u003cstrong\u003e$1.32B\u003c\/strong\u003e of notional foreign currency hedging contracts, mainly for euro, Australian dollar, and Singapore dollar exposure. The company had \u003cstrong\u003e145.06M\u003c\/strong\u003e common shares outstanding and \u003cstrong\u003e45.83M\u003c\/strong\u003e treasury shares, and it repurchased \u003cstrong\u003e523K\u003c\/strong\u003e shares for \u003cstrong\u003e$150M\u003c\/strong\u003e in Q1 2026. These actions support capital structure and risk control, but they do not compete in a product market.\u003c\/p\u003e\n\n\u003cp\u003eThe June 1, 2026 insider tax-withholding sale of \u003cstrong\u003e268.7\u003c\/strong\u003e shares by the general counsel is also administrative. For BCG analysis, that kind of activity belongs in balance-sheet management, not in the dog quadrant. A dog must be a business with weak competitive position and weak growth. Treasury actions do not meet that test.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eForeign exchange hedges reduce earnings volatility.\u003c\/li\u003e\n \u003cli\u003eShare repurchases return capital and can support earnings per share.\u003c\/li\u003e\n \u003cli\u003eTreasury shares affect equity structure, not market demand.\u003c\/li\u003e\n \u003cli\u003eInsider withholding sales are routine compensation-related transactions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMarket sentiment weakness should also not be confused with a dog segment. ResMed's NYSE stock price was \u003cstrong\u003e$196.04\u003c\/strong\u003e on June 8, 2026, while the ASX CDI was down \u003cstrong\u003e26.7%\u003c\/strong\u003e since January 1, 2025. That happened despite FY2025 revenue growth of \u003cstrong\u003e10%\u003c\/strong\u003e, Q2 and Q3 2026 revenue growth of \u003cstrong\u003e11%\u003c\/strong\u003e, and gross margin above \u003cstrong\u003e62%\u003c\/strong\u003e in fiscal 2026 quarters. The company also generated \u003cstrong\u003e$392.6M\u003c\/strong\u003e of net income in Q2 2026 and \u003cstrong\u003e$554M\u003c\/strong\u003e of operating cash flow in Q3 2026. This points to valuation pressure, not a weak operating unit.\u003c\/p\u003e\n\n\u003cp\u003eFor an academic BCG Matrix write-up, the dog quadrant for ResMed is best framed as a narrow set of non-core items rather than a true product segment. You can use this to argue that the company's core businesses remain active and profitable, while the only dog-like elements are restructuring, treasury, and other support costs that do not drive revenue.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601047810197,"sku":"rmd-bcg-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rmd-bcg-matrix.png?v=1740210890","url":"https:\/\/dcf-model.com\/products\/rmd-bcg-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}